Literature DB >> 24743967

MicroRNA clusters: dysregulation in lung adenocarcinoma and COPD.

Sonia Molina-Pinelo1, M Dolores Pastor1, Rocío Suarez1, Beatriz Romero-Romero2, Miriam González De la Peña3, Ana Salinas1, Rocío García-Carbonero4, María José De Miguel3, Francisco Rodríguez-Panadero1, Amancio Carnero1, Luis Paz-Ares5.   

Abstract

Lung adenocarcinoma and chronic obstructive pulmonary disease (COPD) are pulmonary diseases that share common aetiological factors (tobacco smoking) and probable dysregulated pathways. MicroRNAs (miRNAs) play an essential role in regulating numerous physiological and pathological processes. The purpose of this study was to assess global miRNA expression patterns in patients with COPD and/or adenocarcinoma to elucidate distinct regulatory networks involved in the pathogenesis of these two smoking-related diseases. Expression of 381 miRNAs was quantified by TaqMan Human MicroRNA A Array v2.0 in bronchoalveolar lavage fluid samples from 87 patients classified into four groups: COPD, adenocarcinoma, adenocarcinoma with COPD, and control (neither COPD nor adenocarcinoma). 11 differentially expressed miRNAs were randomly selected for validation in an independent cohort of 40 patients. Distinct miRNA expression profiles were identified and validated for each pathological group, involving 66 differentially expressed miRNAs. Four miRNA clusters (the mir-17-92 cluster and its paralogues, mir-106a-363 and mir-106b-25; and the miR-192-194 cluster) were upregulated in patients with adenocarcinoma and one miRNA cluster (miR-132-212) was upregulated in patients with COPD. These results contribute to unravelling miRNA-controlled networks involved in the pathogenesis of adenocarcinoma and COPD, and provide new tools of potential use as biomarkers for diagnosis and/or therapeutic purposes. ©ERS 2014.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24743967     DOI: 10.1183/09031936.00091513

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  35 in total

1.  Kinetics of microRNA Expression in Bronchoalveolar Lavage Fluid Samples.

Authors:  Matthias Brock; Thomas Rechsteiner; Malcolm Kohler; Daniel Franzen; Lars C Huber
Journal:  Lung       Date:  2015-03-21       Impact factor: 2.584

2.  Shifting from Correlation to Causation: Challenges for the Future of Unbiased Molecular Studies in Inflammatory Lung Disease.

Authors:  Stephanie A Christenson; Katrina Steiling
Journal:  Am J Respir Crit Care Med       Date:  2017-01-01       Impact factor: 21.405

3.  Long non-coding RNA NEAT1 predicts elevated chronic obstructive pulmonary disease (COPD) susceptibility and acute exacerbation risk, and correlates with higher disease severity, inflammation, and lower miR-193a in COPD patients.

Authors:  Xiaoyan Ming; Weizhe Duan; Wei Yi
Journal:  Int J Clin Exp Pathol       Date:  2019-08-01

Review 4.  miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives.

Authors:  Mateusz Florczuk; Adam Szpechcinski; Joanna Chorostowska-Wynimko
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.493

5.  Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients.

Authors:  Jens Köhler; Martin Schuler; Thomas Christoph Gauler; Stefanie Nöpel-Dünnebacke; Maike Ahrens; Andreas-Claudius Hoffmann; Stefan Kasper; Felix Nensa; Benedikt Gomez; Maria Hahnemann; Frank Breitenbuecher; Danjouma Cheufou; Filiz Özkan; Kaid Darwiche; Mathias Hoiczyk; Henning Reis; Stefan Welter; Wilfried Ernst Erich Eberhardt; Martin Eisenacher; Helmut Teschler; Georgios Stamatis; Wolff Schmiegel; Stephan Albrecht Hahn; Alexander Baraniskin
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-19       Impact factor: 4.553

Review 6.  Epigenetic targets for novel therapies of lung diseases.

Authors:  Brian S Comer; Mariam Ba; Cherie A Singer; William T Gerthoffer
Journal:  Pharmacol Ther       Date:  2014-11-15       Impact factor: 12.310

7.  microRNA-149-5p mediates the PM2.5-induced inflammatory response by targeting TAB2 via MAPK and NF-κB signaling pathways in vivo and in vitro.

Authors:  Qiuyue Li; Siling Li; Chunjie Xu; Jing Zhao; Lin Hou; Fuyang Jiang; Zhonghui Zhu; Yan Wang; Lin Tian
Journal:  Cell Biol Toxicol       Date:  2021-07-31       Impact factor: 6.691

8.  Ectopic expressed miR-203 contributes to chronic obstructive pulmonary disease via targeting TAK1 and PIK3CA.

Authors:  Liang Shi; Qinghong Xin; Ruonan Chai; Lei Liu; Zhuang Ma
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 9.  Diagnostic Potential of Extracellular MicroRNA in Respiratory Diseases.

Authors:  Dhamotharan Pattarayan; Rajesh K Thimmulappa; Vilwanathan Ravikumar; Subbiah Rajasekaran
Journal:  Clin Rev Allergy Immunol       Date:  2018-06       Impact factor: 8.667

10.  Knockdown of Drosha in human alveolar type II cells alters expression of SP-A in culture: a pilot study.

Authors:  Patricia Silveyra; Zissis C Chroneos; Susan L DiAngelo; Neal J Thomas; Georgios T Noutsios; Nikolaos Tsotakos; Judie A Howrylak; Todd M Umstead; Joanna Floros
Journal:  Exp Lung Res       Date:  2014-07-24       Impact factor: 2.459

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.